Home › Funds › DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. › AZN

DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. position in AZN

ASTRAZENECA PLC · Health Care

DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. reported holding 30,000 shares of AZN (ASTRAZENECA PLC) in its Q2 2026 13F filing — a position valued at US$5.7M, representing 0.64% of its reported portfolio and ranking #39 among its reported holdings. DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. has disclosed AZN holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)30.00K sh
Reported value held$5.69M
Portfolio Weight0.64%
First reportedQ4 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD.'s AZN position evolved

DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. first disclosed a stake in AZN in Q4 2024 at 16,000 shares (US$1.0M). The position peaked in Q2 2026 at 30,000 shares, worth US$5.7M. Across 7 filings, DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 30,000 shares valued at US$5.7M — an increase of 12,000 shares quarter over quarter.. Notable position changes include a 38% increase in Q1 2025 (shares fell 5% over the following quarter), a 67% increase in Q2 2026 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 16.00K $1.05M New
Q1 2025 22.00K $1.62M Add
Q2 2025 20.00K $1.40M Reduce
Q3 2025 20.00K $1.53M Hold
Q4 2025 21.40K $1.97M Add
Q1 2026 18.00K $3.55M Reduce
Q2 2026 30.00K $5.69M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AZN and 13F data

AZN (ASTRAZENECA PLC) is a Health Care company. 71 other funds we track also report a position in AZN — the largest reported positions include Evelyn Partners Group Ltd (US$41.52B), Banque Cantonale Vaudoise (US$11.31B), INVESTOR AB (US$9.78B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AZN

All AZN fund holders →

FAQ

How long has DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. held AZN?

DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. has disclosed AZN holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD.'s current position in AZN?

As of Q2 2026, DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. holds 30.00K shares of AZN (ASTRAZENECA PLC), valued at $5.69M, representing 0.64% of its reported portfolio and ranking #39.

Has DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. been buying or selling AZN?

In the latest 13F filing (Q2 2026), DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. increased its position in AZN. The position peaked in Q2 2026 at 30.00K shares.

Which other funds hold AZN?

Other major institutional holders of AZN include Evelyn Partners Group Ltd, Banque Cantonale Vaudoise, INVESTOR AB, among 71 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.